BioLineRx and Ayrmid Forge Licensing Agreement for Motixafortide via Gamida Cell
BioLineRx Partners with Ayrmid: A Game Changer for Stem Cell Mobilization In a significant move for the biotechnology sector, BioLineRx (NASDAQ: BLRX) has entered into a strategic licensing agreement with Ayrmid, the parent company of … Read more